Figure 6

CD5+ ILC1 demonstrate short-term increments upon CladT within the helper ILC compartment. (a) CD5+ ILC1 and CD5− ILC1 as cells/mL in MS patients at baseline (prior, n = 12), and 2 (2M, n = 10), and 6 months (6M, n = 12) following administration of CladT. (b) CD5+ ILC1 and CD5−ILC1 as %Lin−CD56−CD94−CD127+ helper ILC (%Helper ILC) in MS patients at prior (n = 12), 2M (n = 10), and 6M (n = 12) following administration of CladT. A linear mixed-effects model was calculated to compare between MS patients before and after treatment. 4999 permutations were then run to calculate p-values. Holm’s corrections were used for multiple comparisons which were performed to compare the different timepoints (prior, 2M & 6M). p-values of p < 0.1 are indicated on the graphs.